QRG Capital Management Inc. Grows Holdings in Smith & Nephew SNATS, Inc. $SNN

QRG Capital Management Inc. raised its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 3.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,137 shares of the medical equipment provider’s stock after buying an additional 2,603 shares during the period. QRG Capital Management Inc.’s holdings in Smith & Nephew SNATS were worth $2,700,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Hexagon Capital Partners LLC lifted its stake in shares of Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. raised its position in shares of Smith & Nephew SNATS by 500.0% in the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 1,000 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 1,701 shares during the last quarter. Banque Transatlantique SA purchased a new position in shares of Smith & Nephew SNATS during the 1st quarter valued at approximately $52,000. Finally, Opal Wealth Advisors LLC acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth approximately $73,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

Smith & Nephew SNATS stock opened at $35.94 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. Smith & Nephew SNATS, Inc. has a 12 month low of $23.69 and a 12 month high of $38.79. The company has a fifty day moving average price of $36.25 and a two-hundred day moving average price of $31.29. The company has a market cap of $15.65 billion, a PE ratio of 16.64, a P/E/G ratio of 1.00 and a beta of 0.69.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be given a dividend of $0.285 per share. This represents a dividend yield of 165.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio is currently 26.39%.

Analysts Set New Price Targets

Several research firms recently issued reports on SNN. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Saturday, September 27th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, Canaccord Genuity Group increased their price target on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, August 18th. Seven equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $36.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.